公开(公告)号：WO1998026097A2

公开(公告)日：1998-06-18

申请号：PCT/US1997022665

申请日：1997-12-10

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MACIOSZEK, Jerzy, A. ,  LIN, Bor-Chian ,  MARTINEZ, Arthur, E.

IPC: C12Q01/68

CPC classification number: C12Q1/689 ,  Y02A50/451

Abstract: Nucleic acid sequences that are useful for detecting Legionella pneumophila are herein provided. These sequences can be used in hybridization assays or amplification based assays designed to detect the presence of Legionella pneumophila in a test sample. Additionally, the sequences can be provided as part of a kit.

Abstract translation: 本文提供了可用于检测嗜肺军团杆菌的核酸序列。 这些序列可用于杂交测定或基于扩增的测定，其设计用于检测测试样品中嗜肺军团杆菌的存在。 另外，序列可以作为试剂盒的一部分提供。

公开(公告)号：WO1997007401A1

公开(公告)日：1997-02-27

申请号：PCT/US1996012955

申请日：1996-08-09

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  MACIOSZEK, Jerzy, A. ,  ROBINSON, John, M.

IPC: G01N33/569

CPC classification number: G01N33/56905 ,  G01N33/5306 ,  G01N33/564 ,  G01N2800/102 ,  Y10S435/902 ,  Y10S435/967

Abstract: A method for treating biological samples, e.g., human sera or plasma, suspected of containing rheumatoid factors to eliminate cross-reactivity and false positive assay results in IgM immunoassays that are caused by the presence of rheumatoid factors in these biological samples. In one aspect, the method comprises diluting a biological sample with a sufficient amount of rheumatoid factor neutralization buffer to cause the pH of resulting reaction mixtures containing this sample and a solid phase material to be sufficiently low to cause rheumatoid factors in those mixtures to reduce their affinity to IgG antibodies to such an extent that they will not form a complex with IgG antibodies bound to the solid phase material, thereby facilitating the removal of these rheumatoid factors from the mixtures prior to the detection phase of a diagnostic assay. In another aspect of the invention, the method comprises introducing to a solid phase material containing a binding member-antibody complex a sufficient amount of rheumatoid factor neutralization buffer having a pH sufficiently low to cause rheumatoid factors bound to IgG antibodies bound to the solid phase material to reduce their affinity to the IgG antibodies to such an extent that the rheumatoid factors can be washed away from the solid phase material prior to the detection phase of a diagnostic assay. In either aspect, classes of buffers that are suitable for the method of this invention include ionic, nonionic, and zwitterionic buffers having a pKa value no higher than about 6.5. Representative examples of buffers that are suitable for the method of this invention include, but are not limited to, acetic acid, citric acid, formic acid, and glycine.

Abstract translation: 用于处理怀疑含有类风湿因子以消除交叉反应性和假阳性测定的生物样品例如人血清或血浆的方法导致由这些生物样品中类风湿因子的存在引起的IgM免疫测定。 在一个方面，该方法包括用足量的类风湿因子中和缓冲液稀释生物样品，使得含有该样品和固相物质的所得反应混合物的pH足够低，从而在这些混合物中引起类风湿因子以减少它们 对IgG抗体的亲和力，使得它们不会与结合固相物质的IgG抗体形成复合物，从而有助于在诊断测定的检测阶段之前从混合物中除去这些类风湿因子。 在本发明的另一方面，该方法包括向含有结合成员 - 抗体复合物的固相物质中引入足够量的具有足够低的pH的类风湿因子中和缓冲液以引起与固相物质结合的IgG抗体结合的类风湿因子 以降低其对IgG抗体的亲和力，使得在诊断测定的检测阶段之前类风湿因子可以从固相材料中洗去。 在任一方面，适用于本发明方法的缓冲液类别包括pKa值不高于约6.5的离子，非离子和两性离子缓冲液。 适用于本发明方法的缓冲液的代表性实例包括但不限于乙酸，柠檬酸，甲酸和甘氨酸。

公开(公告)号：EP0948648A2

公开(公告)日：1999-10-13

申请号：EP97952361.0

申请日：1997-12-10

Applicant: Abbott Laboratories

Inventor： MACIOSZEK, Jerzy, A. ,  LIN, Bor-Chian ,  MARTINEZ, Arthur, E.

IPC: C12N15 ,  C12Q1

CPC classification number: C12Q1/689 ,  Y02A50/451

Abstract: Nucleic acid sequences that are useful for detecting Legionella pneumophila are herein provided. These sequences can be used in hybridization assays or amplification based assays designed to detect the presence of Legionella pneumophila in a test sample. Additionally, the sequences can be provided as part of a kit.

公开(公告)号：EP0846268B1

公开(公告)日：2003-01-29

申请号：EP96927361.4

申请日：1996-08-09

Applicant: Abbott Laboratories

Inventor： MACIOSZEK, Jerzy, A. ,  ROBINSON, John, M.

IPC: G01N33/569 ,  G01N33/564 ,  G01N33/543 ,  G01N33/68

CPC classification number: G01N33/56905 ,  G01N33/5306 ,  G01N33/564 ,  G01N2800/102 ,  Y10S435/902 ,  Y10S435/967

Abstract: A method for treating biological samples, e.g., human sera or plasma, suspected of containing rheumatoid factors to eliminate cross-reactivity and false positive assay results in IgM immunoassays that are caused by the presence of rheumatoid factors in these biological samples. In one aspect, the method comprises diluting a biological sample with a sufficient amount of rheumatoid factor neutralization buffer to cause the pH of resulting reaction mixtures containing this sample and a solid phase material to be sufficiently low to cause rheumatoid factors in those mixtures to reduce their affinity to IgG antibodies to such an extent that they will not form a complex with IgG antibodies bound to the solid phase material, thereby facilitating the removal of these rheumatoid factors from the mixtures prior to the detection phase of a diagnostic assay. In another aspect of the invention, the method comprises introducing to a solid phase material containing a binding member-antibody complex a sufficient amount of rheumatoid factor neutralization buffer having a pH sufficiently low to cause rheumatoid factors bound to IgG antibodies bound to the solid phase material to reduce their affinity to the IgG antibodies to such an extent that the rheumatoid factors can be washed away from the solid phase material prior to the detection phase of a diagnostic assay. In either aspect, classes of buffers that are suitable for the method of this invention include ionic, nonionic, and zwitterionic buffers having a pKa value no higher than about 6.5. Representative examples of buffers that are suitable for the method of this invention include, but are not limited to, acetic acid, citric acid, formic acid, and glycine.

公开(公告)号：EP0846268A1

公开(公告)日：1998-06-10

申请号：EP96927361.0

申请日：1996-08-09

Applicant: Abbott Laboratories

Inventor： MACIOSZEK, Jerzy, A. ,  ROBINSON, John, M.

IPC: G01N33

CPC classification number: G01N33/56905 ,  G01N33/5306 ,  G01N33/564 ,  G01N2800/102 ,  Y10S435/902 ,  Y10S435/967

Abstract: A method for treating biological samples, e.g., human sera or plasma, suspected of containing rheumatoid factors to eliminate cross-reactivity and false positive assay results in IgM immunoassays that are caused by the presence of rheumatoid factors in these biological samples. In one aspect, the method comprises diluting a biological sample with a sufficient amount of rheumatoid factor neutralization buffer to cause the pH of resulting reaction mixtures containing this sample and a solid phase material to be sufficiently low to cause rheumatoid factors in those mixtures to reduce their affinity to IgG antibodies to such an extent that they will not form a complex with IgG antibodies bound to the solid phase material, thereby facilitating the removal of these rheumatoid factors from the mixtures prior to the detection phase of a diagnostic assay. In another aspect of the invention, the method comprises introducing to a solid phase material containing a binding member-antibody complex a sufficient amount of rheumatoid factor neutralization buffer having a pH sufficiently low to cause rheumatoid factors bound to IgG antibodies bound to the solid phase material to reduce their affinity to the IgG antibodies to such an extent that the rheumatoid factors can be washed away from the solid phase material prior to the detection phase of a diagnostic assay. In either aspect, classes of buffers that are suitable for the method of this invention include ionic, nonionic, and zwitterionic buffers having a pKa value no higher than about 6.5. Representative examples of buffers that are suitable for the method of this invention include, but are not limited to, acetic acid, citric acid, formic acid, and glycine.